Brian G Hunt, PhD
he/they/him/them/his/theirs
Postdoctoral FellowDownloadHi-Res Photo
About
Titles
Postdoctoral Fellow
Education & Training
- PhD
- University of Cincinnati College of Medicine, Cancer Biology/Cancer and Cell Biology (2022)
- BS
- University of Cincinnati College of Arts & Sciences, Chemistry/Biochemistry (2016)
Research
Research at a Glance
Publications Timeline
A big-picture view of Brian G Hunt's research output by year.
12Publications
Publications
2023
RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence.
Hunt BG, Davis JC, Fox LH, Vicente-Muñoz S, Lester C, Wells SI, Waltz SE. RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence. Oncogene 2023 PMID: 37029299, DOI: 10.1038/s41388-023-02688-5.Peer-Reviewed Original ResearchAn Introduction and Overview of RON Receptor Tyrosine Kinase Signaling.
Hunt BG, Fox LH, Davis JC, Jones A, Lu Z, Waltz SE. An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling. Genes (Basel) 2023, 14 PMID: 36833444, DOI: 10.3390/genes14020517.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2022
Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
Brown NE, Jones A, Hunt BG, Waltz SE. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling. Prostate 2022, 82: 1422-1437. PMID: 35860905, DOI: 10.1002/pros.24416.Peer-Reviewed Original ResearchNMR-based metabolomic analysis identifies RON-DEK-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival.
Vicente-Muñoz S, Hunt BG, Lange TE, Wells SI, Waltz SE. NMR-based metabolomic analysis identifies RON-DEK-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival. PLoS One 2022, 17: e0274128. PMID: 36067206, DOI: 10.1371/journal.pone.0274128.Peer-Reviewed Original ResearchRON (MST1R) and HGFL (MST1) Co-Overexpression Supports Breast Tumorigenesis through Autocrine and Paracrine Cellular Crosstalk.
Hunt BG, Jones A, Lester C, Davis JC, Benight NM, Waltz SE. RON (MST1R) and HGFL (MST1) Co-Overexpression Supports Breast Tumorigenesis through Autocrine and Paracrine Cellular Crosstalk. Cancers (Basel) 2022, 14 PMID: 35626096, DOI: 10.3390/cancers14102493.Peer-Reviewed Original ResearchMacrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35.
Ruiz-Torres SJ, Bourn JR, Benight NM, Hunt BG, Lester C, Waltz SE. Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35. Oncogene 2022, 41: 321-333. PMID: 34743208, DOI: 10.1038/s41388-021-02091-y.Peer-Reviewed Original Research
2021
Suppression of Breast Cancer by Small Molecules That Block the Prolactin Receptor.
Borcherding DC, Hugo ER, Fox SR, Jacobson EM, Hunt BG, Merino EJ, Ben-Jonathan N. Suppression of Breast Cancer by Small Molecules That Block the Prolactin Receptor. Cancers (Basel) 2021, 13 PMID: 34071395, DOI: 10.3390/cancers13112662.Peer-Reviewed Original ResearchTumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.
Bourn JR, Ruiz-Torres SJ, Hunt BG, Benight NM, Waltz SE. Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling. Cancer Lett 2021, 503: 75-90. PMID: 33508385, DOI: 10.1016/j.canlet.2021.01.019.Peer-Reviewed Original ResearchGlutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
Wicker CA, Hunt BG, Krishnan S, Aziz K, Parajuli S, Palackdharry S, Elaban WR, Wise-Draper TM, Mills GB, Waltz SE, Takiar V. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Cancer Lett 2021, 502: 180-188. PMID: 33450358, DOI: 10.1016/j.canlet.2020.12.038.Peer-Reviewed Original Research
2020
MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
Hunt BG, Wicker CA, Bourn JR, Lower EE, Takiar V, Waltz SE. MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients. Breast Cancer Res Treat 2020, 181: 529-540. PMID: 32342233, DOI: 10.1007/s10549-020-05653-y.Peer-Reviewed Original Research
Get In Touch
Contacts
Email
Mailing Address
Immunobiology
300 Cedar St, TACS640
New Haven, Connecticut 06519
United States
Locations
Joshi Lab, IBIO, YSM
Lab
The Anlyan Center
300 Cedar Street, Fl 6, Rm S640
New Haven, CT 06519